RU96110047A - METHOD FOR PREVENTING ENDOMETRITIS AFTER KESAREV SECTION - Google Patents

METHOD FOR PREVENTING ENDOMETRITIS AFTER KESAREV SECTION

Info

Publication number
RU96110047A
RU96110047A RU96110047/14A RU96110047A RU96110047A RU 96110047 A RU96110047 A RU 96110047A RU 96110047/14 A RU96110047/14 A RU 96110047/14A RU 96110047 A RU96110047 A RU 96110047A RU 96110047 A RU96110047 A RU 96110047A
Authority
RU
Russia
Prior art keywords
section
kesarev
endometritis
drug
preventing
Prior art date
Application number
RU96110047/14A
Other languages
Russian (ru)
Other versions
RU2133623C1 (en
Inventor
А.Н. Иванян
Р.Я. Мешкова
С.Б. Крюковский
Т.П. Иванова
Original Assignee
Смоленская государственная медицинская академия
Filing date
Publication date
Application filed by Смоленская государственная медицинская академия filed Critical Смоленская государственная медицинская академия
Priority to RU96110047A priority Critical patent/RU2133623C1/en
Priority claimed from RU96110047A external-priority patent/RU2133623C1/en
Publication of RU96110047A publication Critical patent/RU96110047A/en
Application granted granted Critical
Publication of RU2133623C1 publication Critical patent/RU2133623C1/en

Links

Claims (1)

Способ профилактики эндометрита после кесарева сечения, включающий местное применение лекарственного препарата, отличающийся тем, что в качестве лекарственного препарата используют комплекс естественных цитокинов, выделенных из культуры стимулированных фитогемагглютинином мононуклеарных клеток периферической крови самой пациентки с концентрацией белка 150-200 мкг/мл, в количестве 9 мл во время операции на область швов и в полость матки и 6 мл в первые сутки послеоперационного периода.A method for the prevention of endometritis after cesarean section, including topical use of the drug, characterized in that the complex of natural cytokines isolated from the culture of the patient’s peripheral blood mononuclear cells stimulated with phytohemagglutinin with a protein concentration of 150-200 μg / ml, in an amount of 9, is used as a drug ml during surgery on the suture and in the uterine cavity and 6 ml on the first day of the postoperative period.
RU96110047A 1996-05-21 1996-05-21 Method for preventing endometritis as consequence of cesarean section RU2133623C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU96110047A RU2133623C1 (en) 1996-05-21 1996-05-21 Method for preventing endometritis as consequence of cesarean section

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU96110047A RU2133623C1 (en) 1996-05-21 1996-05-21 Method for preventing endometritis as consequence of cesarean section

Publications (2)

Publication Number Publication Date
RU96110047A true RU96110047A (en) 1998-08-10
RU2133623C1 RU2133623C1 (en) 1999-07-27

Family

ID=20180811

Family Applications (1)

Application Number Title Priority Date Filing Date
RU96110047A RU2133623C1 (en) 1996-05-21 1996-05-21 Method for preventing endometritis as consequence of cesarean section

Country Status (1)

Country Link
RU (1) RU2133623C1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2699029C1 (en) * 2018-12-10 2019-09-03 Частное образовательное учреждение дополнительного профессионального образования "Академия медицинского образования имени Федора Ивановича Иноземцева" (ЧОУ ДПО "Академия медицинского образования им. Ф.И. Иноземцева") Method of using mesenchymal stem cells for improving uterine scar condition

Similar Documents

Publication Publication Date Title
Laato et al. Stimulation of wound healing by epidermal growth factor. A dose-dependent effect.
DE69829721D1 (en) Use of activated protein C for the treatment of excessive blood clotting in sepsis
CA2214503A1 (en) Method for treating tumors
ES2138729T3 (en) DIAGNOSTIC METHODS OF PREECLAMPSIA.
IT1275556B (en) PROCESS AND PLANT FOR THE DEHYDRATION OF FORAGE, IN PARTICULARLY FOR THE DEHYDRATION OF THE MEDICAL GRASS
DE69939075D1 (en) Pharmaceutical composition for the prevention and treatment of diseases associated with cell diseases of the fundus
PT941110E (en) UTILIZATION OF THE FACTOR 2 OF GROWTH OF CERATINOCITES
RU96110047A (en) METHOD FOR PREVENTING ENDOMETRITIS AFTER KESAREV SECTION
CA2091134A1 (en) Therapeutic agent for threatened abortion
ATE79265T1 (en) AGENT FOR THE TREATMENT OF MYCOTIC, MICROBIC AND OTHER TISSUE-DAMAGING AND PATHOLOGICAL MANIFESTATIONS AND TISSUE DEFORMATIONS.
DK0588477T3 (en) Medical preparation comprising TCF-11
EP0279867A3 (en) Use of vitamin e and combinations of vitamin e with anti-inflammatory agents and analgesics in the treatment of rheumatic diseases
KR100488038B1 (en) New bpc peptide salts with organo-protective activity the process for their preparation and their use in therapy
AU4058789A (en) Medicinal drug, method of treatment of human diseases therewith, and method and device for producing and preserving thereof
FI952170A0 (en) Stable preparation of coagulation-promoting active substance for the treatment of coagulation disorders in the blood
Neuhaus et al. Hepatic production of serum alpha2 and beta globulins in rats after injury
DAHL et al. Zinc therapy of acetazolamide‐induced side‐effects
AU3065789A (en) Clinical testing, monitoring and pharmaceutical compositions for treatment of auto-immune diseases
KR900017599A (en) Pharmaceutical composition for tumor treatment
Atkinson et al. Subminimum inhibitory concentrations of antibiotics.
CA2405265A1 (en) Method of preventing or treating diabetes
RU96103305A (en) METHOD FOR THERAPY OF Cervical Uterus VIRAL ETIOLOGY
RU97101024A (en) METHOD FOR ASSESSING SURGICAL AGGRESSION IN OPERATIONS ON THE ABDOMINAL CAVITY
张丽珠 THE IVF PROGRAM AT BEIJING MEDICAL UNIVERSITY~
Voorhees Topical Minoxidil, Experimental and Clinical Results: Editor’s Introduction